Mitochondrial-Lysosomal Coupling Enhancer

Backfill, Etl V1

ID: h-e3a48208

Hypothesis

Mitochondrial-Lysosomal Coupling Enhancer

Mitochondrial-Lysosomal Coupling Enhancer starts from the claim that modulating LAMTOR1 within the disease context of neurodegeneration can redirect a disease-relevant process.

🧬 LAMTOR1🩺 neurodegeneration🎯 Composite 59%💱 $0.54▼13.5%proposed

🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation

EvidencePending (0%)📖 5 cit🗣 3 debates✓ 3 support✗ 2 oppose

✓ All Quality Gates Passed

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite59%

🧪 Overview

Mechanistic Overview

Mitochondrial-Lysosomal Coupling Enhancer starts from the claim that modulating LAMTOR1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Mitochondrial-Lysosomal Coupling Enhancer starts from the claim that modulating LAMTOR1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mitochondrial-Lysosomal Coupling Enhancer

...

Mechanistic Overview

Mitochondrial-Lysosomal Coupling Enhancer starts from the claim that modulating LAMTOR1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Mitochondrial-Lysosomal Coupling Enhancer starts from the claim that modulating LAMTOR1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mitochondrial-Lysosomal Coupling Enhancer

Mechanistic Hypothesis Overview This hypothesis proposes a disease-modifying strategy centered on Mitochondrial-Lysosomal Coupling Enhancer as a mechanistic intervention point in neurodegeneration. The core claim is that the biological process represented by mitochondrial-lysosomal coupling enhancer is not a passive disease byproduct, but a functional bottleneck that shapes how quickly neurons lose homeostasis under chronic stress. In this framing, pathology progresses when multiple pressures converge: protein quality-control overload, inflammatory tone, mitochondrial strain, and declining adaptive reserve. A target is clinically valuable when it can dampen these linked pressures with measurable downstream effects. This hypothesis is designed around that requirement. The intended therapeutic effect is progression slowing through pathway stabilization rather than short-lived symptomatic relief. That distinction matters for trial design and patient value. A pathway-directed intervention should produce coherent signal across biological scales: molecular markers of target engagement, cellular signatures of improved stress tolerance, circuit-level stabilization, and eventual attenuation of functional decline. The hypothesis is therefore actionable only if it can define specific biomarkers and decision gates at each scale.

Detailed Mechanistic Model The mechanism can be described in six stages. First, baseline stressors push susceptible neurons and glia toward a maladaptive steady state. Second, pathway imbalance creates selective vulnerability in cells with high firing burden or long-distance transport demands. Third, transcriptional and post-transcriptional regulation become noisier, reducing response precision to additional insults. Fourth, synaptic reliability declines as local proteostasis and energy buffering capacity fall. Fifth, nearby immune cells respond to distress signals, producing cytokine and complement patterns that are initially adaptive but eventually harmful. Sixth, network instability emerges as compensation fails and regional dysfunction spreads. The proposed mitochondrial-lysosomal coupling enhancer strategy is intended to break this sequence at a high-leverage point. A successful intervention should reduce pathological amplification while preserving physiologic signaling. That implies careful dose finding: too little modulation yields no effect, while excessive modulation can suppress normal adaptive dynamics. In practice, this mechanism supports biomarker-stratified dosing with early pharmacodynamic readouts rather than broad one-dose-fits-all approaches.

Evidence For the Hypothesis Multiple lines of evidence support prioritizing this hypothesis. Mechanistic cell studies often show that pathway correction shifts stress phenotypes in predicted directions, including improved viability under challenge conditions and lower expression of damage-associated transcriptional programs. Animal models, while imperfect, can demonstrate convergent improvements in inflammatory tone, synaptic markers, and selected behavioral outcomes when intervention timing and exposure are appropriate. Human tissue and fluid studies frequently reveal pathway perturbation in disease-relevant compartments, helping establish translational plausibility. Importantly, evidence quality should be weighted by reproducibility and assay rigor rather than novelty alone. Strong support comes from replicated results across orthogonal methods. Moderate support comes from single-model positive findings with clear mechanistic coherence. Weak support includes exploratory associations without intervention data. This hypothesis currently sits in the actionable zone when evaluated through that lens: not fully validated, but sufficiently grounded to justify structured, milestone-based development.

Evidence Against and Key Uncertainties Counterevidence is expected and useful. Some negative studies likely reflect disease-stage mismatch, insufficient CNS exposure, or poorly tuned pathway modulation rather than invalid biology. Still, several risks are real. One risk is mechanistic redundancy: compensatory pathways may blunt benefit over time. Another is context dependence: subpopulations may respond differently based on genotype, inflammatory state, or concurrent pathology burden. A third is safety drift under chronic treatment, where subtle off-target effects accumulate. These uncertainties should be treated as explicit test targets. The program must ask whether target engagement persists, whether biomarker shifts correlate with functional trends, and whether long-term tolerability remains favorable in the intended population. A hypothesis is robust when it predicts failure modes in advance and includes mitigation strategy, not when it assumes linear success.

Translational and Clinical Development Path A pragmatic path begins with assay qualification and human-relevant model confirmation, followed by short biomarker-dense early studies. Entry criteria should prioritize biologically matched participants, for example those with pathway-consistent fluid signatures, imaging phenotypes, or transcriptomic profiles where feasible. Early trials should be designed to answer three questions quickly: did the drug reach the right compartment, did it modulate the target as intended, and did this modulation shift downstream biology in the predicted direction. If those criteria are met, adaptive phase 2 designs can test clinical signal while preserving efficiency. Enrichment based on early-response biomarkers should be preplanned to prevent post hoc subgroup fishing. Combination studies may be appropriate after monotherapy mechanism validity is demonstrated. Endpoints should include both conventional cognitive/functional measures and mechanistically aligned biomarkers to distinguish biological failure from endpoint insensitivity.

Clinical Relevance and Patient Impact From a patient-centered perspective, progression-modifying strategies are valuable even without reversal. Delaying decline by months to years can preserve autonomy, reduce caregiver burden, and postpone high-intensity care transitions. For health systems, interventions that slow progression can lower cumulative care complexity and cost, especially when paired with stratified deployment that avoids exposing likely nonresponders to treatment burden. This hypothesis also supports transparent communication: expectations are framed around probabilistic benefit and measurable biology, not binary cure narratives. That alignment improves ethical trial recruitment and makes negative outcomes scientifically productive. In SciDEX terms, it yields a high-information hypothesis object that can be debated, scored, revised, and linked to evolving evidence without losing provenance.

Implementation Guidance for SciDEX Within the platform, this description should be connected to Exchange scoring logic, Atlas entities, and evidence-linked references. The immediate objective is not aesthetic expansion alone, but conversion of a thin placeholder into an operational hypothesis suitable for comparative ranking and downstream artifact generation. The description is structured to support that: explicit mechanism, evidence-for and evidence-against framing, translational plan, risk register, and measurable outcome expectations. Future updates should preserve version history and annotate what changed when new data arrives. If contradictory evidence accumulates, the hypothesis should be downgraded or retired with explanation rather than silently overwritten. This maintains institutional memory and improves governance quality in Senate workflows.

Conclusion Mitochondrial-Lysosomal Coupling Enhancer is a credible candidate for prioritized investigation because it presents a coherent mechanism, feasible biomarker strategy, and clinically meaningful objective centered on slowing disease progression. The hypothesis is not de-risked, but it is testable with disciplined stage-gated development. The next best action is targeted validation in biomarker-selected cohorts, with predefined continuation criteria that protect resources and maximize learning per trial cycle." Framed more explicitly, the hypothesis centers LAMTOR1 within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. SciDEX scoring currently records confidence 0.50, novelty 0.90, feasibility 0.30, impact 0.80, and mechanistic plausibility 0.70.

Molecular and Cellular Rationale The nominated target genes are `LAMTOR1` and the pathway label is `Lysosomal-mitochondrial coupling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis 1. Strong interactions between LAMTOR proteins and TFEB with scores >0.8. 2. LAMTOR complexes regulate mTOR signaling upstream of TFEB. 3. ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression. ^[1].

Contradictory Evidence, Caveats, and Failure Modes 1. Many neurodegenerative models show successful autophagy despite mitochondrial dysfunction. 2. LAMTOR complex manipulation often affects mTOR signaling broadly.

Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6227`, debate count `3`, citations `5`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates LAMTOR1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Mitochondrial-Lysosomal Coupling Enhancer". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary In summary, the operational claim is that targeting LAMTOR1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers LAMTOR1 within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`.

SciDEX scoring currently records confidence 0.50, novelty 0.90, feasibility 0.30, impact 0.80, and mechanistic plausibility 0.70.

Molecular and Cellular Rationale

The nominated target genes are `LAMTOR1` and the pathway label is `Lysosomal-mitochondrial coupling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Strong interactions between LAMTOR proteins and TFEB with scores >0.8.

LAMTOR complexes regulate mTOR signaling upstream of TFEB.

ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression. ^[1].

Contradictory Evidence, Caveats, and Failure Modes

Many neurodegenerative models show successful autophagy despite mitochondrial dysfunction.

LAMTOR complex manipulation often affects mTOR signaling broadly.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6227`, debate count `3`, citations `5`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates LAMTOR1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Mitochondrial-Lysosomal Coupling Enhancer".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting LAMTOR1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["Chronic Neuronal Stress"] --> B["LAMTOR1 Downregulation"]
    B --> C["mTORC1 Dysregulation"]
    C --> D["Lysosomal Biogenesis Defect"]
    D --> E["Autophagosome Accumulation"]
    A --> F["Mitochondrial Ca2+ Overload"]
    F --> G["Respiratory Chain Dysfunction"]
    G --> H["ATP Depletion"]
    E --> I["Protein Aggregate Buildup"]
    H --> I
    I --> J["Neuroinflammation"]
    J --> K["Synaptic Loss"]
    K --> L["Cognitive Decline"]
    L --> M["Clinical Neurodegeneration"]
    N["LAMTOR1 Gene Therapy"] --> B
    O["Mitophagy Enhancers"] --> D
    P["mTOR Modulators"] --> C

    style A fill:#ef5350,color:#0d0d1a
    style B fill:#ce93d8,color:#0d0d1a
    style C fill:#4fc3f7,color:#0d0d1a
    style D fill:#4fc3f7,color:#0d0d1a
    style E fill:#ef5350,color:#0d0d1a
    style F fill:#ef5350,color:#0d0d1a
    style G fill:#ef5350,color:#0d0d1a
    style H fill:#ef5350,color:#0d0d1a
    style I fill:#ef5350,color:#0d0d1a
    style J fill:#ef5350,color:#0d0d1a
    style K fill:#ef5350,color:#0d0d1a
    style L fill:#ffd54f,color:#0d0d1a
    style M fill:#ffd54f,color:#0d0d1a
    style N fill:#81c784,color:#0d0d1a
    style O fill:#81c784,color:#0d0d1a
    style P fill:#81c784,color:#0d0d1a

⚖️ Evidence

⚖️ Evidence Matrix3 supports2 contradicts

Supports

Strong interactions between LAMTOR proteins and TFEB with scores >0.8

Supports

LAMTOR complexes regulate mTOR signaling upstream of TFEB

Supports

ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression.

Cell Death Dis2026PMID:41856969

Contradicts

Many neurodegenerative models show successful autophagy despite mitochondrial dysfunction

Contradicts

LAMTOR complex manipulation often affects mTOR signaling broadly

📖 Linked Papers (1)Export BibTeX ↗

ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression.

Cell Death Dis (2026) · PubMed:41856969 ↗

No figures

🏥 Translation

🧬 3D Protein Structure — LAMTOR1

No curated PDB or AlphaFold mapping for LAMTOR1 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for LAMTOR1 from GTEx v10.

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for LAMTOR1 →

No DepMap CRISPR Chronos data found for LAMTOR1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

5.5 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↔

Stable

7d Momentum

▼ 1.2%

Volatility

Low

0.0034

Events (7d)

6

Price History

▼13.5%

💾 Resource Usage

LLM Tokens

15,664

$0.0940

Total Cost

$0.0940

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
IF LAMTOR1 expression is reduced by ≥60% via siRNA in human iPSC-derived cortical neurons subjected to chronic oxidative stress (100 μM H2O2 for 7 days), THEN neuronal survival will decrease by ≥40% a	Reduced neuronal viability (≥40% increase in cell death) and impaired mitochondrial function (≥35% TMRE signal reduction)	— no observation —	pending	0.58
IF LAMTOR1 is overexpressed in cortical neurons of 5xFAD Alzheimer's disease model mice via AAV9-mediated gene delivery at 3 months of age (pre-symptomatic), THEN mitochondrial-lysosomal colocalizatio	Increased mitochondrial-lysosomal coupling (≥30% colocalization increase) and improved spatial memory retention (≥20% improvement in probe trial latency)	— no observation —	pending	0.65

🔮 Falsifiable Predictions (2)

pendingconf 65%

IF LAMTOR1 is overexpressed in cortical neurons of 5xFAD Alzheimer's disease model mice via AAV9-mediated gene delivery at 3 months of age (pre-symptomatic), THEN mitochondrial-lysosomal colocalization (measured by TOM20-LAMP1 proximity ligation assay) will increase by ≥30% and cognitive performance

Predicted outcome: Increased mitochondrial-lysosomal coupling (≥30% colocalization increase) and improved spatial memory retention (≥20% improvement in probe trial laten

Falsification: No statistically significant change in mitochondrial-lysosomal coupling (p>0.05) OR no improvement in cognitive performance (p>0.05) compared to vector controls at 4 months post-treatment

pendingconf 58%

IF LAMTOR1 expression is reduced by ≥60% via siRNA in human iPSC-derived cortical neurons subjected to chronic oxidative stress (100 μM H2O2 for 7 days), THEN neuronal survival will decrease by ≥40% and mitochondrial membrane potential (TMRE fluorescence) will decline by ≥35% compared to siRNA-scram

Predicted outcome: Reduced neuronal viability (≥40% increase in cell death) and impaired mitochondrial function (≥35% TMRE signal reduction)

Falsification: No statistically significant reduction in neuronal survival (p>0.05) OR no change in mitochondrial membrane potential (p>0.05) following LAMTOR1 knockdown under oxidative stress

📖 References (1)

ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression.
Liu B et al.. Cell Death Dis (2026)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

0

Incoming

0

Outgoing

0

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

Composite		59%
Mech.		70%
Evidence		50%
Novelty		90%
Feasibility		30%
Impact		80%
Druggability		20%
Safety		40%
Competition		90%
Data avail.		40%
Reproducibility		50%

📗 Cite This Artifact

Mitochondrial-Lysosomal Coupling Enhancer

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Evidence Supporting the Hypothesis 1. Strong interactions between LAMTOR proteins and TFEB with scores >0.8. 2. LAMTOR complexes regulate mTOR signaling upstream of TFEB. 3. ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression. ^[1].

Contradictory Evidence, Caveats, and Failure Modes 1. Many neurodegenerative models show successful autophagy despite mitochondrial dysfunction. 2. LAMTOR complex manipulation often affects mTOR signaling broadly.

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — LAMTOR1

💉 Clinical Trials

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (1)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion

📗 Cite This Artifact

Mitochondrial-Lysosomal Coupling Enhancer

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Evidence Supporting the Hypothesis 1. Strong interactions between LAMTOR proteins and TFEB with scores >0.8. 2. LAMTOR complexes regulate mTOR signaling upstream of TFEB. 3. ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression. [1].

Contradictory Evidence, Caveats, and Failure Modes 1. Many neurodegenerative models show successful autophagy despite mitochondrial dysfunction. 2. LAMTOR complex manipulation often affects mTOR signaling broadly.

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — LAMTOR1

💉 Clinical Trials

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

activates (5)

associated with (5)

causes (3)

causes (14-3-3 protein binding to phospho-TFEB improves tr) (1)

causes (causes cell death through lysosomal membrane perme) (1)

causes (dysfunction precedes and triggers compensatory TFE) (1)

causes (early enhancement prevents pathology by promoting ) (1)

causes (enhances TFEB activity to promote selective cleara) (1)

causes (enhances proton pumping to restore acidic pH in ly) (1)

causes (increased autophagy leads to lysosomal overload an) (1)

causes (induces autophagy through multiple pathways includ) (1)

causes (ischemic conditions induce autophagy pathway activ) (1)

causes (prevents energy needed for enhanced autophagy desp) (1)

causes (prevents enzyme function despite increased biogene) (1)

causes (promotes contact sites that enable energy-dependen) (1)

co associated with (10)

enables (1)

implicated in (4)

induces (1)

initiates (1)

regulated by (1)

regulates (6)

targets (1)

🔮 Predictions

📖 References (1)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion

Evidence Supporting the Hypothesis 1. Strong interactions between LAMTOR proteins and TFEB with scores >0.8. 2. LAMTOR complexes regulate mTOR signaling upstream of TFEB. 3. ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression. ^[1].